Holen Sie sich die Stockscreener-App
17.09
0.70%
-0.12
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St
Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
(RIGL) Trading Signals - Stock Traders Daily
Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St
Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail
Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve
Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat
Rigel Pharmaceuticals announces initial data from Phase 1b study of R289 - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
(RIGL) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Jacobs Levy Equity Management Inc. Has $2.87 Million Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - MarketBeat
Rigel Pharmaceuticals, Inc. Appoints Keith A. Katkin to its Board of Directors - Marketscreener.com
PDT Partners LLC Purchases New Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA - TipRanks
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS - PR Newswire
Rigel Pharma's Blood Disorder Drug R289 Wins FDA Fast Track Status for MDS Treatment - StockTitan
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Decline in Short Interest - MarketBeat
How To Trade (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
SEC Form 4 filed by CEO, President Rodriguez Raul R - Quantisnow
Warm Autoimmune Hemolytic Anemia Market to Observe Stupendous Growth During the Forecast Period (2020-2034) | Rigel Pharmaceuticals, Bioverativ (Sanofi), Incyte, Johnson & Johnson - The Globe and Mail
Rigel Pharmaceuticals, Inc. Appoints Dean Schorno as Executive Vice President and Chief Financial Officer - Marketscreener.com
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus.com
Rigel Pharmaceuticals : Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update - Marketscreener.com
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% - MSN
Rigel Pharmaceuticals To Present At Jefferies London Healthcare Conference; Webcast At 4:30 AM ET - Nasdaq
(RIGL) Proactive Strategies - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Reduces Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $33.38 Average PT from Analysts - MarketBeat
Rigel Pharmaceuticals price target raised to $23 from $15 at Piper Sandler - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00 at Piper Sandler - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Rigel Pharmaceuticals price target raised to $49 from $40 at Citi - TipRanks
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges - Investing.com
Citi raises Rigel Pharma stock target, buy rating on strong Gavreto sales - Investing.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rigel stock rallies 36% after Q3 earnings beat - MSN
Rigel Pharmaceuticals stock hits 52-week high at $17.5 By Investing.com - Investing.com Australia
Earnings call: Rigel Pharmaceuticals reports strong Q3 growth, plans expansion - Investing.com Canada
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):